Trial Profile
A retrospective study to evaluate the effect of gefitinib dose reduction in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2015
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 06 Nov 2015 New trial record